Bisphosphonates and cancer

Rowan J. Milner, James Farese, Carolyn J. Henry, Kim Selting, Timothy M. Fan, Louis Philippe De Lorimier

Research output: Contribution to journalReview article

Abstract

Bisphosphonates form a family of drugs characterized pharmacologically by their ability to inhibit bone resorption and pharmacokinetically by similar intestinal absorption, skeletal distribution, and renal elimination. Two groups of bisphosphonates exist chemically, non-amino-bisphosphates and amino-bisphosphonates. The amino-bisphosphonates have greater antiresorptive capabilities and represent a newer generation of bisphosphonates. The primary mechanism of action of bisphosphonates is inhibition of osteoclastic activity. Non-amino-bisphosphonates are incorporated into the energy pathways of the osteoclast, resulting in disrupted cellular energy metabolism leading to apoptosis. Amino-bisphosphonates exert their effect on osteoclasts via their inhibition of the mevalonate pathways, resulting in disruption of intracellular signaling and induction of apoptosis. Bisphosphonates also inhibit cancer cell proliferation, induce apoptosis in in vitro cultures, inhibit angiogenesis, inhibit matrix metalloproteinase, have effects on cytokine and growth factors, and are immunomodulatory. Clinical applications in oncology could include therapy for hypercalcemia of malignancy, inhibition of bone metastasis, and therapy for bone pain. Although bisphosphonates are regarded as metabolically inert in the body, adverse effects do occur and include esophagitis, gastritis, suppression of bone repair, and allergic reactions. Little is published on the effects of bisphosphonates in dogs with cancer. Further research into the role of bisphosphonates in veterinary oncology is needed to identify clinical efficacy and safety of these potentially beneficial drugs.

Original languageEnglish (US)
Pages (from-to)597-604
Number of pages8
JournalJournal of veterinary internal medicine
Volume18
Issue number5
DOIs
StatePublished - Sep 1 2004

Fingerprint

Diphosphonates
osteoclasts
apoptosis
bones
neoplasms
esophageal diseases
hypercalcemia
drugs
Neoplasms
therapeutics
gastritis
bone resorption
intestinal absorption
metalloproteinases
angiogenesis
hypersensitivity
in vitro culture
metastasis
energy metabolism
growth factors

Keywords

  • Adverse effects
  • Alendronate
  • Etidronate
  • Hypercalcemia of malignancy
  • Multiple myeloma
  • Osteosarcoma
  • Pamidronate
  • Zoledronate

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Bisphosphonates and cancer. / Milner, Rowan J.; Farese, James; Henry, Carolyn J.; Selting, Kim; Fan, Timothy M.; De Lorimier, Louis Philippe.

In: Journal of veterinary internal medicine, Vol. 18, No. 5, 01.09.2004, p. 597-604.

Research output: Contribution to journalReview article

Milner, Rowan J. ; Farese, James ; Henry, Carolyn J. ; Selting, Kim ; Fan, Timothy M. ; De Lorimier, Louis Philippe. / Bisphosphonates and cancer. In: Journal of veterinary internal medicine. 2004 ; Vol. 18, No. 5. pp. 597-604.
@article{4b7885e8e5a8435ca6aa431f863084b1,
title = "Bisphosphonates and cancer",
abstract = "Bisphosphonates form a family of drugs characterized pharmacologically by their ability to inhibit bone resorption and pharmacokinetically by similar intestinal absorption, skeletal distribution, and renal elimination. Two groups of bisphosphonates exist chemically, non-amino-bisphosphates and amino-bisphosphonates. The amino-bisphosphonates have greater antiresorptive capabilities and represent a newer generation of bisphosphonates. The primary mechanism of action of bisphosphonates is inhibition of osteoclastic activity. Non-amino-bisphosphonates are incorporated into the energy pathways of the osteoclast, resulting in disrupted cellular energy metabolism leading to apoptosis. Amino-bisphosphonates exert their effect on osteoclasts via their inhibition of the mevalonate pathways, resulting in disruption of intracellular signaling and induction of apoptosis. Bisphosphonates also inhibit cancer cell proliferation, induce apoptosis in in vitro cultures, inhibit angiogenesis, inhibit matrix metalloproteinase, have effects on cytokine and growth factors, and are immunomodulatory. Clinical applications in oncology could include therapy for hypercalcemia of malignancy, inhibition of bone metastasis, and therapy for bone pain. Although bisphosphonates are regarded as metabolically inert in the body, adverse effects do occur and include esophagitis, gastritis, suppression of bone repair, and allergic reactions. Little is published on the effects of bisphosphonates in dogs with cancer. Further research into the role of bisphosphonates in veterinary oncology is needed to identify clinical efficacy and safety of these potentially beneficial drugs.",
keywords = "Adverse effects, Alendronate, Etidronate, Hypercalcemia of malignancy, Multiple myeloma, Osteosarcoma, Pamidronate, Zoledronate",
author = "Milner, {Rowan J.} and James Farese and Henry, {Carolyn J.} and Kim Selting and Fan, {Timothy M.} and {De Lorimier}, {Louis Philippe}",
year = "2004",
month = "9",
day = "1",
doi = "10.1892/0891-6640(2004)18<597:BAC>2.0.CO;2",
language = "English (US)",
volume = "18",
pages = "597--604",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Bisphosphonates and cancer

AU - Milner, Rowan J.

AU - Farese, James

AU - Henry, Carolyn J.

AU - Selting, Kim

AU - Fan, Timothy M.

AU - De Lorimier, Louis Philippe

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Bisphosphonates form a family of drugs characterized pharmacologically by their ability to inhibit bone resorption and pharmacokinetically by similar intestinal absorption, skeletal distribution, and renal elimination. Two groups of bisphosphonates exist chemically, non-amino-bisphosphates and amino-bisphosphonates. The amino-bisphosphonates have greater antiresorptive capabilities and represent a newer generation of bisphosphonates. The primary mechanism of action of bisphosphonates is inhibition of osteoclastic activity. Non-amino-bisphosphonates are incorporated into the energy pathways of the osteoclast, resulting in disrupted cellular energy metabolism leading to apoptosis. Amino-bisphosphonates exert their effect on osteoclasts via their inhibition of the mevalonate pathways, resulting in disruption of intracellular signaling and induction of apoptosis. Bisphosphonates also inhibit cancer cell proliferation, induce apoptosis in in vitro cultures, inhibit angiogenesis, inhibit matrix metalloproteinase, have effects on cytokine and growth factors, and are immunomodulatory. Clinical applications in oncology could include therapy for hypercalcemia of malignancy, inhibition of bone metastasis, and therapy for bone pain. Although bisphosphonates are regarded as metabolically inert in the body, adverse effects do occur and include esophagitis, gastritis, suppression of bone repair, and allergic reactions. Little is published on the effects of bisphosphonates in dogs with cancer. Further research into the role of bisphosphonates in veterinary oncology is needed to identify clinical efficacy and safety of these potentially beneficial drugs.

AB - Bisphosphonates form a family of drugs characterized pharmacologically by their ability to inhibit bone resorption and pharmacokinetically by similar intestinal absorption, skeletal distribution, and renal elimination. Two groups of bisphosphonates exist chemically, non-amino-bisphosphates and amino-bisphosphonates. The amino-bisphosphonates have greater antiresorptive capabilities and represent a newer generation of bisphosphonates. The primary mechanism of action of bisphosphonates is inhibition of osteoclastic activity. Non-amino-bisphosphonates are incorporated into the energy pathways of the osteoclast, resulting in disrupted cellular energy metabolism leading to apoptosis. Amino-bisphosphonates exert their effect on osteoclasts via their inhibition of the mevalonate pathways, resulting in disruption of intracellular signaling and induction of apoptosis. Bisphosphonates also inhibit cancer cell proliferation, induce apoptosis in in vitro cultures, inhibit angiogenesis, inhibit matrix metalloproteinase, have effects on cytokine and growth factors, and are immunomodulatory. Clinical applications in oncology could include therapy for hypercalcemia of malignancy, inhibition of bone metastasis, and therapy for bone pain. Although bisphosphonates are regarded as metabolically inert in the body, adverse effects do occur and include esophagitis, gastritis, suppression of bone repair, and allergic reactions. Little is published on the effects of bisphosphonates in dogs with cancer. Further research into the role of bisphosphonates in veterinary oncology is needed to identify clinical efficacy and safety of these potentially beneficial drugs.

KW - Adverse effects

KW - Alendronate

KW - Etidronate

KW - Hypercalcemia of malignancy

KW - Multiple myeloma

KW - Osteosarcoma

KW - Pamidronate

KW - Zoledronate

UR - http://www.scopus.com/inward/record.url?scp=6444220920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6444220920&partnerID=8YFLogxK

U2 - 10.1892/0891-6640(2004)18<597:BAC>2.0.CO;2

DO - 10.1892/0891-6640(2004)18<597:BAC>2.0.CO;2

M3 - Review article

C2 - 15515572

AN - SCOPUS:6444220920

VL - 18

SP - 597

EP - 604

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 5

ER -